Pharmacokinetics of Monoclonal Antibodies.
Pharmacokinetics of Monoclonal Antibodies.
复制标题
DOI：
10.1002/psp4.12224
复制
发表时间：
2017-09
期刊：
影响因子：
--
通讯作者：
Meibohm B
中科院分区：
文献类型：
--
作者：
Ryman JT;Meibohm B
单克隆抗体 (mAb) 在过去二十年中已发展成为多种适应症药物治疗干预的支柱，目前美国食品和药物管理局批准了 40 多种单克隆抗体，还有数十种处于临床开发阶段。本教程将回顾与 mAb 相关的主要药物处置过程，并将重点介绍调节其药代动力学 (PK) 行为以及成功临床治疗所需考虑的产品特异性和患者特异性因素。
Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for mAbs, and will highlight product‐specific and patient‐specific factors that modulate their pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.